Shilpa Medicare Receives SEC Approval for Novel Injectable OERIS
Shilpa Medicare Ltd 路 Press Release 路 11 Sept 2026, 6:55 pm
Shilpa Medicare Receives SEC Approval for Novel Injectable OERIS Shilpa Medicare received final approval on 11th Sep'26 from the Subject Expert Committee under CDSCO for marketing authorization of OERIS (Ondansetron Extended-Release Injection, 100 mg/mL). Designed as the world's first extended-release ondansetron injection, OERIS provides up to 120 hours of antiemetic protection from a single dose for chemotherapy-induced nausea and vomiting. Backed by successful Phase III trials, the product holds Indian patent protection until 2039. The company plans a commercial rollout across India upon receiving final marketing authorization from CDSCO.
Original exchange filing (PDF)
More announcements from Shilpa Medicare Ltd
- Q2FY27 Earnings Conference Call 05 November 2026 路 11 Nov 2026
- Audio link of the Investor Conference call for the quarter ended 30 September 2026. 路 06 Nov 2026
- Update on Corporate Insolvency Resolution Process of FTF Pharma Private Limited, a Wholly Owned Subsidiary of Shilpa Medicare Limited 路 05 Nov 2026
- Investor Presentation for the Quarter and Half year ended 30 September 2026 路 05 Nov 2026
- Outcome of the Board Meeting 路 05 Nov 2026
- Shilpa Medicare Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026. 路 05 Nov 2026
- Financial Results for the Quarter and Half year ended 30 September 2026 路 05 Nov 2026
- SHILPA MEDICARE LIMITED has informed the Exchange about Board Meeting to be held on 05-Nov-2026 to inter-alia consider and approve the Unaudited Financial results of the Company for the Half Yearly ended September 2026 . 路 05 Nov 2026
